1. What Is the Size Exclusion Chromatography Market?
The Size Exclusion Chromatography Market encompasses chromatography systems, columns, resins, and consumables that separate molecules according to hydrodynamic size as they pass through a porous gel filtration medium. Larger molecules elute first, separating biomolecules by molecular weight without chemical interaction. The market includes gel filtration columns for protein aggregate removal in biopharmaceutical polishing steps and analytical SEC-HPLC columns for protein purity and aggregation analysis. It also includes preparative SEC systems for biomolecule fractionation and SEC-MALS detection systems for molecular weight characterisation. These products are used by biopharmaceutical manufacturers for aggregate and fragment removal in downstream polishing and by quality control laboratories for protein purity and aggregation monitoring throughout the manufacturing process. Market scope covers size exclusion chromatography media, analytical and preparative SEC columns, and integrated SEC-HPLC system configurations for biopharmaceutical manufacturing and laboratory applications, and excludes non-size-exclusion affinity, ion exchange, and reversed phase chromatography modes.
2. Size Exclusion Chromatography Market Size & Forecast
3. Emerging Technologies
- Miniaturised analytical SEC chip technology is advancing microfluidic chip-based SEC separation platforms that perform aggregate and molecular weight analysis from sub-microliter protein sample volumes, enabling high-throughput screening of expression and purification. Growing biopharmaceutical process.
- Long-lifetime SEC column technology is advancing crosslinked polymer and zwitterionic surface chemistry SEC columns with improved column lifetime under repeated CIP and high sample load conditions, reducing per-analysis column costs in high-throughput. Growing biopharmaceutical.
- SEC-DLS integration is advancing coupled size exclusion chromatography and dynamic light scattering detection systems that provide simultaneous SEC purity profile and hydrodynamic size distribution from each eluting protein fraction. Growing biopharmaceutical analytical scientist interest.
- Continuous SEC buffer exchange technology is advancing annular chromatography and simulated moving bed SEC configurations for continuous desalting and buffer exchange that replace batch preparative gel filtration. Growing industry adoption of this technology is motivating development.
Such innovations are driving change across adjacent industries too. Discover more in our Continuous Chromatography Market.
4. Key Market Opportunity
A key opportunity in the Size Exclusion Chromatography Market is the development of high-resolution SEC column platforms for oligonucleotide and RNA therapeutic analysis as the growing siRNA, antisense, and mRNA therapeutic pipeline creates demand for SEC methods capable of resolving oligonucleotide length variants and aggregates. A significant proportion of oligonucleotide and RNA therapeutic programmes in clinical development require analytical methods for sequence variant, aggregate, and impurity characterisation that conventional protein SEC columns do not adequately resolve. Dedicated oligonucleotide SEC column chemistries providing baseline resolution of length variants and RNA aggregates are needed for regulatory-compliant nucleic acid therapeutic quality control and clinical stability method validation. SEC column manufacturers that develop and validate oligonucleotide and RNA-specific column chemistries with regulatory submission packages, demonstrate length variant and aggregate resolution from clinical-grade nucleic acid therapeutic samples, and provide method development toolkits are positioned to capture the growing RNA therapeutic analytical SEC market.
5. Top Companies in the Size Exclusion Chromatography Market
The following organisations hold leading positions in the Size Exclusion Chromatography Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Waters Corporation
- Cytiva (GE Healthcare)
- Tosoh Bioscience
- Agilent Technologies
- Bio-Rad Laboratories
- Merck Millipore
- Phenomenex
- Ymc America
- Advanced Materials Technology
- Sepax Technologies
6. Market Segmentation
The Size Exclusion Chromatography Market is analysed across 5 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Mode | Analytical SEC SEC-HPLC Protein Analysis SEC-MALS Molecular Weight Preparative SEC Preparative Gel Filtration Buffer Exchange Desalting Process-Scale SEC GMP Polishing Column Aggregate Removal Step |
| By Matrix | Agarose Bead Crosslinked Agarose-Dextran Allyl Dextran Crosslinked Polyacrylamide Bead Polyacrylamide Gel Bead Dextran Crosslinked Crosslinked Dextran Gel Silica SEC Analytical SEC Silica Column Polymer Bead |
| By Application | Antibody Aggregate Analysis IgG Purity SEC Bispecific mAb SEC Protein Polishing Aggregate Removal Downstream Buffer Exchange Protein Buffer Desalting Oligonucleotide Separation siRNA SEC Analysis Vaccine Characterisation Virus-Like Particle SEC |
| By End User | Biopharmaceutical Manufacturers QC SEC Analytical Downstream Processing SEC Academic Research Life Sciences Research Labs Analytical Testing Laboratories CRO SEC Testing Vaccine Manufacturers Vaccine Lot Release SEC |
| By Geography | North America Europe Asia Pacific Latin America Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Size Exclusion Chromatography Market trajectory over the forecast period:
High-Resolution SEC Column Technology Is Enabling Sub-0_5 Percent Aggregate Detection in Biopharmaceutical Quality Control.Biopharmaceutical quality control scientists performing protein aggregate analysis for regulatory release testing are adopting high-resolution SEC-HPLC columns including Waters BioResolve and Tosoh TSKgel UP-SW that provide sufficient resolution to distinguish. Dimer, higher oligomers at sub-0_5 percent abundance for ICH Q6B compliance. Waters Corporation continued commercial development of BioResolve SEC column products with sub-2-micron particle technology for ultra-high-resolution protein aggregate analysis in 2024. This provides biopharmaceutical QC laboratories with improved aggregate separation resolution for advanced complex antibody and fusion protein products.
Multi-Attribute Method SEC Integration Is Replacing Multiple Separate Analytical Tests with a Single Combined SEC-Mass Spectrometry Platform.Biopharmaceutical analytical development scientists are implementing multi-attribute method workflows that couple SEC separation with high-resolution mass spectrometry detection. This enables simultaneous aggregate quantification, protein identity confirmation, glycoform analysis, and post-translational modification profiling from a single analytical run. Agilent Technologies and Waters Corporation continued development of SEC-MS coupling platforms and multi-attribute method software for biopharmaceutical analytical characterisation in 2024, providing analytical scientists with integrated SEC-MS system solutions for comprehensive protein product quality monitoring.
Preparative SEC Desalting Technology Is Providing Efficient Buffer Exchange as an Alternative to Ultrafiltration-Diafiltration in Process Development.Biopharmaceutical process development scientists evaluating buffer exchange options for formulation step are comparing preparative gel filtration desalting columns against tangential flow filtration as an alternative that provides superior aggregate removal during buffer exchange. Simultaneously achieving the required formulation buffer transfer. Cytiva continued commercial development of Sephadex and HiPrep desalting SEC columns and Bio-Rad maintained the Econo-Pac DG10 desalting column portfolio in 2024. This provides process development scientists with validated preparative desalting SEC formats from laboratory scale to pilot scale.
For related market intelligence, see the Affinity Chromatography Market.
8. Segmental Analysis
By mode, analytical SEC dominated the Size Exclusion Chromatography Market in 2025, driven by the large biopharmaceutical QC laboratory base performing routine SEC aggregate analysis for every monoclonal antibody and biologic lot release testing worldwide. Biopharmaceutical QC scientists continue generating the highest SEC consumable demand as ICH Q6B purity characterisation requirements mandate SEC aggregate testing for every lot release, clinical stability sample, and regulatory submission. Process-scale SEC is the fastest-growing mode, driven by growing biopharmaceutical downstream processing adoption of aggregate removal SEC polishing steps and continuous SEC configurations for integration into continuous manufacturing platforms. Downstream processing scientists are increasing process-scale SEC adoption as aggregate depletion polishing provides complementary aggregate removal beyond Protein A capture while avoiding ion-exchange conditions that can compromise protein structure.
By application, antibody aggregate analysis dominated the Size Exclusion Chromatography Market in 2025, driven by the universal requirement for IgG monomer purity quantification by SEC in monoclonal antibody QC release and clinical stability testing. Biopharmaceutical QC scientists continue specifying SEC as the primary analytical method for IgG aggregate quantification as SEC is the FDA and EMA reference method for antibody aggregate and fragment analysis in lot release testing. Oligonucleotide separation is the fastest-growing application, driven by the growing siRNA, antisense oligonucleotide, and mRNA therapeutic pipeline requiring SEC analytical methods for nucleic acid purity and aggregate characterisation. Analytical scientists in RNA and oligonucleotide therapeutic programmes are increasing SEC adoption for nucleic acid characterisation as growing clinical pipeline volumes create demand for validated SEC methods for purity and aggregate analysis.
9. Regional Analysis
Regional demand patterns across the Size Exclusion Chromatography Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America accounted for the largest share of the Size Exclusion Chromatography Market in 2025, holding 42.0% of the global market. The region's dominance reflects the large United States biopharmaceutical QC laboratory base requiring routine SEC aggregate analysis for every mAb lot release, the concentration of major SEC column manufacturers with North American commercial headquarters, and the high volume of clinical-stage biopharmaceutical development requiring analytical SEC characterisation at CROs and pharmaceutical laboratories. The large United States biopharmaceutical manufacturing and development sector generates the highest global analytical SEC consumable demand as routine protein purity and aggregate analysis by SEC is required for every production batch, clinical stability sample, and regulatory submission characterisation package. Growing United States RNA therapeutic and oligonucleotide drug development pipeline is creating expanding demand for specialised analytical SEC methods for nucleic acid aggregate and sequence variant analysis beyond conventional protein SEC column applications.
Highest CAGR Region
Asia Pacific is expected to register the highest CAGR of 10.50% during the forecast period. Growing biopharmaceutical manufacturing capacity, expanding CRO and analytical testing laboratory infrastructure, and increasing biosimilar and novel biopharmaceutical development investment in China, South Korea, Japan, India, and Singapore are creating demand for analytical SEC columns and systems. Growing Chinese biopharmaceutical manufacturing quality control requirement for SEC aggregate analysis at domestic mAb manufacturing facilities is creating large-volume analytical SEC column consumable demand as Chinese manufacturers expand regulated QC testing infrastructure. Growing academic life sciences research investment and expanding CRO sector analytical service capacity in South Korea, Singapore, and India are creating demand for SEC-HPLC systems and columns for protein characterisation and biopharmaceutical analytical method development.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Size Exclusion Chromatography Market was valued at USD 1.82 Bn in 2025 and is projected to reach USD 3.48 Bn by 2034, growing at a CAGR of 7.50% over the 2026–2034 forecast period.
The Size Exclusion Chromatography Market is projected to grow at a CAGR of 7.50% from 2026 to 2034.
North America accounted for the largest share of the Size Exclusion Chromatography Market in 2025, holding 42.0% of the global market.
The leading companies in the Size Exclusion Chromatography Market include Waters Corporation, Cytiva (GE Healthcare), Tosoh Bioscience, Agilent Technologies, Bio-Rad Laboratories, Merck Millipore, Phenomenex, Ymc America, Advanced Materials Technology, Sepax Technologies.
High-resolution sec column technology is enabling sub-0_5 percent aggregate detection in biopharmaceutical quality control.
By mode, analytical SEC dominated the Size Exclusion Chromatography Market in 2025, driven by the large biopharmaceutical QC laboratory base performing routine SEC aggregate analysis for every monoclonal antibody and biologic lot release testing worldwide.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.